Your browser doesn't support javascript.
loading
Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients.
Abudayyeh, Ala; Lin, Heather; Abdelrahim, Maen; Rondon, Gabriela; Andersson, Borje S; Martinez, Charles S; Page, Valda D; Tarrand, Jeffrey J; Kontoyiannis, Dimitrios P; Marin, David; Oran, Betul; Olson, Amanda; Jones, Roy; Popat, Uday; Champlin, Richard E; Chemaly, Roy F; Shpall, Elizabeth J; Rezvani, Katayoun.
Affiliation
  • Abudayyeh A; Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Abdelrahim M; Institute of Academic Medicine and Weill Cornell Medical College, Houston Methodist Cancer Center, Houston, TX, USA.
  • Rondon G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Andersson BS; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Martinez CS; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Page VD; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tarrand JJ; Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kontoyiannis DP; Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Marin D; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Oran B; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Olson A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jones R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Popat U; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chemaly RF; Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rezvani K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Transpl Infect Dis ; 22(5): e13395, 2020 Oct.
Article in En | MEDLINE | ID: mdl-32602954
ABSTRACT

BACKGROUND:

BK polymavirus (BKPyV), a member of the family Polyomaviridae, is associated with increased morbidity and mortality in allogeneic stem cell transplant recipients.

METHODS:

In our previous retrospective study of 2477 stem cell transplant patients, BKPyV replication independently predicted chronic kidney disease and poor survival. In this study, using the same cohort, we derived and validated a risk grading system to identify patients at risk of BKPyV replication after transplantation in a user-friendly modality. We used 3 baseline variables (conditioning regimen, HLA match status, and underlying cancer diagnosis) that significantly predicted BKPyV replication in our initial study in a subdistribution hazard model with death as a competing risk. We also developed a nomogram of the hazard model as a visual aid. The AUC of the ROC of the risk-score-only model was 0.65. We further stratified the patients on the basis of risk score into low-, moderate-, and high-risk groups.

RESULTS:

The total risk score was significantly associated with BKPyV replication (P < .0001). At 30 days after transplantation, the low-risk (score ≤ 0) patients had a 9% chance of developing symptomatic BKPyV replication, while the high-risk (score ≥ 8) of the population had 56% of developing BKPyV replication. We validated the risk score using a separate cohort of 1478 patients. The AUC of the ROC of the risk-score-only model was 0.59. Both the total risk score and 3-level risk variable were significantly associated with BKPyV replication in this cohort (P < .0001).

CONCLUSIONS:

This grading system for the risk of symptomatic BKPyV replication may help in early monitoring and intervention to prevent BKPyV-associated morbidity, mortality, and kidney function decline.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Virus Infections / Kidney Transplantation / BK Virus / Hematopoietic Stem Cell Transplantation / Polyomavirus Infections Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Transpl Infect Dis Journal subject: TRANSPLANTE Year: 2020 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Virus Infections / Kidney Transplantation / BK Virus / Hematopoietic Stem Cell Transplantation / Polyomavirus Infections Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Transpl Infect Dis Journal subject: TRANSPLANTE Year: 2020 Type: Article Affiliation country: United States